Physician profile
Daniel Degruttola
NPI 1790737815
$3,731.10
in general payments reported to CMS, 2019-2025
15 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 90% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $98.65 · 2021: $139 · 2022: $219 · 2023: $748 · 2024: $1,095 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,136.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,458.11 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $547.94 | 2024-2025 | Fanapt |
| Indivior INC. | $471.14 | 2019-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $375.62 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $223.20 | 2023-2025 | Auvelity |
| Abbvie INC. | $215.09 | 2023-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $100.71 | 2023-2025 | Rexulti |
| Braeburn INC. | $96.37 | 2025 | Brixadi |
| Orexo US, INC. | $78.75 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $76.24 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $24.88 | 2025 | Uzedy |
| Biodelivery Sciences International, INC. | $16.70 | 2021 | |
| Gilead Sciences, INC. | $16.10 | 2021 | |
| Lundbeck LLC | $15.40 | 2023 | Rexulti |
| Alkermes, INC. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Degruttola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.